Skip to content
Tirzepatide Report
Provider review

Coivas Tirzepatide Review: Starting Price & Refund Terms (2026)

Published by Tirzepatide ReportUpdated

On this page

Tirzepatide from $199/month, with a named clinical network and a strict six-month guarantee.

Standout details

  • Names Beluga Health as current clinical provider
  • Medication and ongoing clinical support marketed in one package

Things to consider

  • Starting headline does not establish selected total or commitment
  • No individual preparing pharmacy named in current network FAQ

Coivas advertises tirzepatide from $199 per month, with prescription care, medication and ongoing support marketed as one package. The starting figure does not establish your selected plan's whole bill, commitment length or every-dose price. Confirm those details before payment rather than treating the headline as an unconditional monthly quote.3

The other important distinction is its money-back guarantee. The current Terms require at least six consecutive months of paid enrollment and a verified final weight no lower than the starting weight, plus substantial adherence and verification conditions. This is not a general right to return medication or stop early for a refund.4

Price and care included

The homepage distinguishes tirzepatide's $199 starting figure from semaglutide's $119. It markets no membership fees, a prescription, medication shipment and access to clinicians and the care team. The publicly displayed headline alone does not specify the full selected payment schedule or the quantity in each shipment.3

A same-medication, same-plan price-lock promise appears in its FAQ. The Terms nevertheless allow prices to change with 30 days' notice. Ask which protection applies to your purchase and whether a change in treatment or package alters the amount. A price-lock statement is not an every-dose flat-price guarantee across different plans.3,4

Coivas · Price and care

Buyer questionPublished detail
Tirzepatide headlineFrom $199/month
Package marketingPrescription, medication and ongoing support
Clinical networkBeluga Health named on current homepage
Preparing pharmacy503A/503B network; dispenser can vary
Price changesSame-plan lock claim versus 30-day notice in Terms
The advertised starting price does not establish the complete selected payment schedule.

Who provides treatment?

Coivas is a technology platform connecting patients with independent clinicians, not itself the treating medical provider or dispensing pharmacy. The Terms open with WellVi LLC d/b/a Coivas, while their contact section names Coivas Health, Inc. The current homepage identifies Beluga Health as the clinical provider.3,4

The pharmacy FAQ describes a network of 503A compounding pharmacies and 503B outsourcing facilities, with the actual dispenser varying by location, medication, availability and provider preference. That is a description of a network, not identification or independent verification of your preparing facility. Its nationwide availability statement also does not guarantee a specific prescription can be supplied in your state.3

Compounded medication is not an FDA-approved finished product, and the branded preparation used in a clinical trial is not proof of the compounded product's performance. Read our explanation of compounded tirzepatide's legal status before comparing the two routes.

Cancellation and ordinary refunds

The homepage says to cancel through the patient portal before the next shipment is processed to avoid the next charge. Once processing has occurred, cancellation applies to the following billing cycle. The Return Policy describes period-end cancellation and says used partial periods are generally nonrefundable. Obtain the actual processing date instead of assuming the delivery date is the cancellation deadline.3,5

An uncompleted paid consultation qualifies for a consultation-fee refund. That is different from completing an assessment and receiving no prescription: the latter membership-fee cases are reviewed individually, with a refund where appropriate. Completed visits and nondefective delivered medication are generally nonrefundable. Wrong, damaged or compromised medication should be reported within seven days; confirmed defects can qualify for replacement or a refund. Approved ordinary refunds are processed within five to ten business days.5

The six-month guarantee

To qualify, a first-time customer must verify starting weight within seven days unless otherwise confirmed, remain continuously enrolled and follow clinical instructions and refill requirements. Pauses, failed payments, enrollment gaps, switching to a brand product or a microdosing protocol can invalidate the guarantee. Outside weight-loss medication is also restricted. These conditions make the headline much narrower than an unconditional satisfaction promise.4

Claims are due within 40 days of the final medication shipment. Verification requires a professional attestation within 14 days of the claim email or a coded video within 24 hours of receiving the code. Eligible subscription payments may be refunded after approval; incidental costs are excluded, processing can take 30 days after verification approval, and the guarantee offers no partial refund for leaving early.4

Coivas · Refund boundaries

Buyer questionPublished detail
Cancel next cycleBefore shipment processing; confirm date
Uncompleted paid visitConsultation-fee refund
No prescription after assessmentMembership-fee case reviewed individually
Results guaranteeAt least six continuous paid months; no verified loss
Guarantee claimWithin 40 days of final shipment
Early departureNo partial guarantee refund
Clinical-denial review, ordinary refunds and the six-month guarantee are separate policies.

Discuss Zepbound side effects, gallbladder risk and the thyroid cancer warning with your clinician. Testimonials and advertised delivery or prescribing timelines cannot establish your eligibility or treatment outcome.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-11, and better than semaglutide head-to-head2 — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

Is Coivas worth comparing?

Coivas supplies useful public financial rules and names a clinical network, but its low starting price needs a selected plan and its guarantee requires a substantial commitment. Compare the actual purchase terms with Care Clinics, Emerge Weight Loss, Kina, Lumora and Remi Meds without assuming shared clinicians, refund rules or medication costs. Our provider comparison can help organize the questions to ask before committing.

Frequently asked questions

Is the $199 Coivas tirzepatide price a confirmed month-to-month rate?

It is a published starting figure, not a complete selected quote. Confirm the commitment, amount due, shipment supply and renewal schedule before payment.3

Who supplies clinical care and compounds the medication?

The homepage names Beluga Health as clinical provider. It describes 503A/503B pharmacy partners, with the dispenser varying by location and prescription; this does not identify your assigned facility.3

Can I cancel for a full refund if I do not lose weight?

Not simply by leaving early. The guarantee requires at least six consecutive paid months, no verified loss and adherence, refill and verification conditions. It is not prorated.4

Do I get my money back if no prescription is issued?

A paid consultation that never occurred qualifies for its fee refund. After an assessment with no prescription, membership-fee refunds are considered individually. These are distinct from the strict results guarantee.5

References(5)

  1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, and the SURMOUNT-1 Investigators (2022). Tirzepatide Once Weekly for the Treatment of Obesity.. New England Journal of Medicine. PMID: 35658024. Read source
  2. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Bays HE, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5).. New England Journal of Medicine. PMID: 40353578. Read source
  3. Coivas (2026). Current tirzepatide starting price, inclusions and provider FAQ (accessed October 25, 2026). Coivas.
  4. Coivas (2026). Terms of Service (July 6, 2026; live six-month guarantee accessed October 25, 2026). Coivas.
  5. Coivas (2026). Return Policy (May 7, 2026; accessed October 25, 2026). Coivas.

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.